Cargando…

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis

Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Won-Young, Kim, Han-Jo, Kim, Kyoungha, Bae, Sang-Byung, Lee, Namsu, Lee, Kyu-Taek, Won, Jong-Ho, Park, Hee-Sook, Lee, Sang-Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843730/
https://www.ncbi.nlm.nih.gov/pubmed/25761487
http://dx.doi.org/10.4143/crt.2014.234
_version_ 1782428676548198400
author Park, Won-Young
Kim, Han-Jo
Kim, Kyoungha
Bae, Sang-Byung
Lee, Namsu
Lee, Kyu-Taek
Won, Jong-Ho
Park, Hee-Sook
Lee, Sang-Cheol
author_facet Park, Won-Young
Kim, Han-Jo
Kim, Kyoungha
Bae, Sang-Byung
Lee, Namsu
Lee, Kyu-Taek
Won, Jong-Ho
Park, Hee-Sook
Lee, Sang-Cheol
author_sort Park, Won-Young
collection PubMed
description Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis.
format Online
Article
Text
id pubmed-4843730
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-48437302016-05-06 Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis Park, Won-Young Kim, Han-Jo Kim, Kyoungha Bae, Sang-Byung Lee, Namsu Lee, Kyu-Taek Won, Jong-Ho Park, Hee-Sook Lee, Sang-Cheol Cancer Res Treat Case Report Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis. Korean Cancer Association 2016-04 2015-03-02 /pmc/articles/PMC4843730/ /pubmed/25761487 http://dx.doi.org/10.4143/crt.2014.234 Text en Copyright © 2016 by the Korean Cancer Association This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Park, Won-Young
Kim, Han-Jo
Kim, Kyoungha
Bae, Sang-Byung
Lee, Namsu
Lee, Kyu-Taek
Won, Jong-Ho
Park, Hee-Sook
Lee, Sang-Cheol
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
title Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
title_full Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
title_fullStr Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
title_full_unstemmed Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
title_short Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
title_sort intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843730/
https://www.ncbi.nlm.nih.gov/pubmed/25761487
http://dx.doi.org/10.4143/crt.2014.234
work_keys_str_mv AT parkwonyoung intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis
AT kimhanjo intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis
AT kimkyoungha intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis
AT baesangbyung intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis
AT leenamsu intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis
AT leekyutaek intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis
AT wonjongho intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis
AT parkheesook intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis
AT leesangcheol intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis